- Company
- Hugel signs distribution partnership agreement with Benev
- by Nho, Byung Chul Jul 2, 2024 05:49am
- The global total medical aesthetics company Hugel(Chair: Suk-yong Cha) will officially enter the U.S. market through a strategic partnership with the U.S.-based Benev Company. The company began discussions on a partnership to sell its botulinum toxin product ‘(Letybo, Korean brand name: Botulax)’ in the U.S. in August last year, and f
- Company
- PNH drug Voydeya is approved…new treatment option for PNH
- by Hwang, Byung-woo Jul 2, 2024 05:49am
- A new option for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) has been introduced in Korea with the approval of Voydeya (danicopan), a first-in-class oral factor D inhibitor. Voydeya is AstraZeneca Korea's PNH treatment that was approved by the Ministry of Food and Drug Safety (MFDS) on March 28th. Voydeya is a first-in
- Company
- GLP-1 uses↑…targets MASH, diabetes, and obesity
- by Son, Hyung-Min Jul 1, 2024 05:48am
- New drug candidates of the GLP-1 class target metabolic dysfunction-associated steatohepatitis (MASH) in addition to diabetes and obesity. Global pharmaceutical companies, such as Novo Nordisk, Eli Lily, Boehringer Ingelheim, and Korean pharmaceutical companies, including Dong-A ST and D&D pharmatech, are developing GLP-1 agents for the treat
- Company
- Companies to focus on developing trispecific antibodies
- by Son, Hyung-Min Jul 1, 2024 05:48am
- The pharmaceutical industry in South Korea and overseas has begun developing trispecific antibodies that bind three targets. Previously, these companies focused on bispecific antibodies, which can bind simultaneously to two different antigens or two antigenic epitopes on a single antigen. Crossing the blood-brain barrier (BBB) can increase th
- Company
- Various treatment options introduced for multiple myeloma
- by Eo, Yun-Ho Jul 1, 2024 05:48am
- New treatment options for multiple myeloma treatment are emerging one after another. According to industry sources on the 28th, drugs such as Pfizer’s ‘Elrexfio (elranatamab)’ and GSK’s ‘Blenrep((belantamab mafodotin)’ are receiving attention as promising candidates in the field of multiple myeloma. In the case of Elrexfio, the d
- Company
- Samsung Bioepis targets Stelara market
- by Hwang, Byung-woo Jul 1, 2024 05:47am
- Samsung Bioepis is seeking to target the Stelara (Ustekinumab) market by directly marketing its Stelara biosimilar Epyztek in Korea. The company is adding Epyztek to the list of autoimmune disease treatments it has been selling directly since March, a strategy that is expected to strengthen its marketing capabilities while increasing profita
- Company
- Ilaris’s reimbursement imminent in Korea
- by Eo, Yun-Ho Jul 1, 2024 05:47am
- The ultra-rare disease treatment Ilaris has finally passed the final hurdle to its reimbursement in Korea. Novartis Korea recently completed drug price negotiations with the National Health Insurance Service for Ilaris (canakinumab), a treatment for hereditary periodic fever syndrome. The company was quick to accept the conditional ben
- Company
- GC Cell-Artiva-MSD’s 'CAR-NK' co-R&D deal terminated
- by Kim, Jin-Gu Jun 28, 2024 04:33am
- GC Cell and Artiva Biotherapeutic’s collaborative research and development (R&D) agreement with MSD for ‘CAR-NK solid tumor treatment’ has been terminated. MSD informed Artiva Biotherapeutic, GC Cell’s U.S. subsidiary, of the contract termination. As a result, Artiva Biotherapeutic and GC Cell’s research agreement has been automatic
- Company
- KOD will service platform for epilepsy patients next year
- by Lee, Tak-Sun Jun 28, 2024 04:33am
- A platform for epilepsy patients and healthcare professionals will soon be launched in Korea. Japan's Knock on the Door (KOD) announced in May that it has established its branch in Seoul and is preparing to launch the service next year. KOD was established in Tokyo, Japan, in 2018 with the goal of "Realizing a society where patients
- Company
- MSD seeks to expand NIP subjects for Gardasil
- by Hwang, Byung-woo Jun 28, 2024 04:33am
- With the aim of expanding coverage of its human papillomavirus (HPV) vaccine within the National Immunization Program (NIP), MSD Korea has been working to improve its vaccine awareness. Expanding NIP coverage of the HPV vaccine is one of the hot topics on the government's agenda. In fact, it was ranked the third-most important task in the 'Es
